La Jolla reactivates Phase III Riquent trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla has reactivated enrollment in a Phase III trial of Riquent (abetimus sodium) in lupus renal disease under a special protocol assessment. The trial is being conducted at FDA's request based on clinical deficiencies relating to the firm's previous Phase II and Phase III trials cited in an October 2004 "approvable" letter (1Pharmaceutical Approvals Monthly November 2004, p. 13). FDA recommended another study to distinguish Riquent from placebo through an endpoint such as time to renal flare. La Jolla plans to enroll 600 patients by the second half of 2007 and has expanded the trial to include Europe and Mexico...
You may also be interested in...
La Jolla’s Long Road To Riquent Approval Takes Another Turn
La Jolla Pharmaceutical is modifying an ongoing Phase III trial evaluating its systemic lupus erythematosus candidate Riquent (abetimus) in a manner that will push back the study findings beyond the latest anticipated timeline
Riquent "Approvable" For Lupus; FDA Says Ongoing Study Could Be Enough
La Jolla Pharmaceuticals hopes running a parallel study alongside the ongoing confirmatory trial for its lupus agent Riquent will satisfy the requirements set out in FDA’s Oct. 14 "approvable" letter.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.